Inner Age Journey:
Blood test with Inside Tracker biomarker Analysis
Ever wonder how old your body is on the inside?
Your blood can reveal early signs of disease and hidden deficiencies that may be making your body age faster. Powered by InsideTracker, this journey identifies aging-related biomarkers in the blood to generate your “Inner Age” (ie: biological age) score.
A Personalized Action Plan for Healthy Aging
Get science-backed nutrition and exercise recommendations based on your blood biomarkers. This action plan is based on your body’s needs and helps you improve your Inner Age by targeting areas that need the most work.
Physician Supervision
Concierge Support
Key Journey Details
White glove blood draw service: work with a dedicated concierge to schedule your blood draw free of hassle. We’re connected to medical centers in all 50 states to make the process as convenient as possible.
Complete blood biomarker analysis: the Inside Tracker test analyzes 15 biomarkers for women and 17 biomarkers for men. This includes indicators for blood sugar, cholesterol, immune cells, inflammation, testosterone, and more.
Your Inner Age score: Inside Tracker uses the biomarkers in your blood to generate an “Inner Age” score for your body. View your score in the Inner Age dashboard and dive deeper into how it was calculated.
Maintenance and improvement: learn which areas of your lifestyle are working and which ones need improvement, with actionable steps for healthy eating, stress reduction, sleep quality, and exercise.
Peer-Reviewed Research
-
2010 ACCF/AHA Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults. Circulation. November 2010.
-
Preventing myocardial infarction in the young adult in the first place: how do the national cholesterol education panel iii guidelines perform? Journal of the American College of Cardiology. May 2003.
-
Coronary Atherosclerotic Precursors of Acute Coronary Syndromes. Journal of the American College of Cardiology. June 2018.
Frequently Asked Questions
-
A Cleerly heart scan analysis provides a detailed look at the presence, amount, and type of plaque in your heart’s arteries, using coronary computed tomography angiography (CCTA). The images from the CCTA are processed by Cleerly’s advanced AI software, which translates the data into measurements and reports for your doctor to review. This analysis gives you and your physician a clear picture of your plaque levels and types, helping to assess heart attack risk and guide personalized treatment plans, including lifestyle changes or medications. Cleerly can also identify arterial narrowing (stenosis), which can impede blood flow and lead to symptoms like chest pain or heart failure.
-
Plaque is a key factor in atherosclerosis, a condition where substances like fat, cholesterol, and calcium accumulate inside the arteries. Over time, plaque can reduce or even block blood flow to the heart, which significantly increases the risk of heart attacks. Certain types of plaque, especially non-calcified, low-density plaques, are more prone to rupture and cause a heart attack. The good news is that these plaques can often be stabilized with lifestyle changes and medical treatments. Cleerly helps you track the percentage of non-calcified plaque and monitor its stability over time.
-
Coronary computed tomography angiography (CCTA) is a specialized imaging test that assesses the heart’s blood vessels for plaque buildup. It uses computed tomography (CT), commonly known as a CT or CAT scan, to create multiple images of your heart and its arteries. These images can be analyzed in 3D, providing detailed insight into the condition of your coronary arteries.
-
As Cleerly is a new diagnostic test, it is not yet fully covered by insurance. Pricing may vary depending on the provider. We recommend discussing costs directly with your doctor and imaging center. If you have heart disease symptoms, some portions of your scan may be covered by insurance.
-
Many traditional heart disease tests, such as those for cholesterol or blood pressure, do not directly detect the presence of heart disease but instead assess risk factors. Shockingly, 70% of heart attack patients were considered "low-risk" by these conventional measures, and more than 90% of stress tests yield normal results. Cleerly uses CCTA, a non-invasive and highly accurate heart scan, to directly analyze plaque levels. This technology allows doctors to make informed decisions about treatment, whether that means additional testing or preventive measures.
-
Cleerly is designed for people who have symptoms of heart disease or those who believe they are at risk, even if they don’t yet have symptoms. Current medical guidelines suggest CCTA as an appropriate test for individuals experiencing chest pain.
-
Cleerly’s technology is backed by over 10 million images from more than 30,000 patients collected over 15 years in multi-center clinical trials. Our AI-driven plaque analysis has been FDA-cleared, and multiple trials have confirmed Cleerly’s accuracy in diagnosing heart disease. These trials demonstrate that Cleerly surpasses all existing clinical gold standards in detecting coronary artery disease.